The United Kingdom and the United States have forged a significant bilateral deal that will keep no tariffs on British drug exports entering the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has committed to increase funding on pharmaceuticals through the NHS. This pledge secures that import taxes on these key products will remain at zero for a duration of 36 months.
This deal follows recent statements to hike duties on branded pharmaceutical imports, with increases mentioned reaching 100%.
"This deal with the Britain bolsters the global environment for new treatments and introduces long-overdue fairness to American-British pharmaceutical trade," a statement declared.
Commercial Importance
Pharmaceuticals are one of the Britain's biggest export categories to the US, which is clearly the biggest buyer for large British pharmaceutical firms.
Trade data show that in the year to the end of the third quarter, the UK exported medicines valued at over eleven billion pounds to the US. This figure represented nearly one-fifth of total UK exports in that timeframe.
"This agreement safeguards jobs, boosts funding and paves the way for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary commented.
Detailed UK Commitments
The deal involves several specific pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it judges new medicines to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a goal to double total health service expenditure on treatments from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must return to the NHS to control costs will be limited at fifteen percent. Last year, repayments exceeded twenty percent.
Industry Background
The pact takes place against a long-running tension between the pharmaceutical industry and the British authorities over medicine costs and approval rates.
This friction were heightened by arguments that US customers were charged significantly more for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or cancelled, while substantial expansions have been pledged toward US facilities.
The Science Minister acknowledged that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a proportion of its total funding over the last ten years.
